These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 17489733

  • 1. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E, Rosell R.
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [Abstract] [Full Text] [Related]

  • 2. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [Abstract] [Full Text] [Related]

  • 11. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.
    Clin Cancer Res; 2008 May 01; 14(9):2878-86. PubMed ID: 18451256
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug 01; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 01; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Excision repair cross complementing-group 1: gene expression and platinum resistance.
    Altaha R, Liang X, Yu JJ, Reed E.
    Int J Mol Med; 2004 Dec 01; 14(6):959-70. PubMed ID: 15547660
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer].
    Han XP, Zhang X.
    Zhonghua Yi Xue Za Zhi; 2010 Aug 10; 90(30):2115-8. PubMed ID: 21029626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.